Objective: To compare the distance between the sphenoid and frontal bones in trisomy 21 and euploid fetuses at 16-24 weeks' gestation by three-dimensional (3D) ultrasound.
Introduction
Ultrasound examination of the fetal profile in the second and third trimesters of pregnancy provides the ability to assess several facial measurements which are significantly different between trisomy 21 and chromosomally normal fetuses.
Previous studies have shown that trisomy 21 fetuses have an increased prevalence of nasal bone absence or hypoplasia 1 , prenasal thickening 2 , wide fronto-maxillary facial angle 3 , increased prenasal thickness-nasal bone length ratio 4 and high prefrontal space ratio 5 .
Postnatal radiologic studies have shown that individuals with trisomy 21 also have a growth reduction in the sagittal portion of the endocranium, the mid-facial area, the cranial base and the frontal bone [6] [7] [8] [9] . These changes lead to vertical hypoplasia of the central structures of the cranium, lowering the position of sella turcica and flattening the cranial base. It has been reported that children and infants with trisomy 21 have a significantly shorter anterior cranial base length compared to controls 8, 9 .
The aim of this study was to compare the distance between the sphenoid and frontal bone, as a measure of the anterior cranial base length, in trisomy 21 and normal fetuses at 16-24 weeks' gestation by three-dimensional (3D) ultrasound.
Methods
We examined the fetal profile using stored 3D ultrasound volumes of the fetal head that had been acquired from pregnant women undergoing an ultrasound examination for any indications at our Fetal Medicine Units between 16 and 24 weeks' gestation.
One operator selected the 3D volumes from two groups of patients. In 50 randomly selected cases, the spheno-frontal distance was measured independently by two operators and in 60 cases by the same operator on two occasions.
Statistical analysis
Regression analysis was used to determine the significance of the association between spheno-frontal distance and gestational age. The Kolmogorov-Smirnov test was used to confirm the normality of the measurements in chromosomally normal and trisomy 21 fetuses. The values of spheno-frontal distance were then expressed as a difference from the appropriate expected mean for gestation (delta value).
Independent samples T-Test was used to compare mean spheno-frontal distance delta values between normal and trisomy 21 fetuses. The Bland-Altman analysis was used to compare the measurement agreement and bias for a single examiner and between two examiners 11 .
The data were analysed using the statistical package IBM SPSS 19.0 (New York, USA) and Excel for Windows 2010 (Microsoft Corp., Redmond, WA, USA). A p value of less than 0.05 was considered statistically significant.
Results
In the 80 normal fetuses, the median maternal age was 32 (range 16-44) years and 
Discussion
The findings of this study provide evidence that the spheno-frontal distance is In this study, the landmarks used to measure the anterior cranial base length were different from those used in radiologic studies. First, only a portion of the sphenoid bone can be usually visualized on obstetric ultrasound in the scanning plane required to obtain the fetal profile, due to shadowing from the anterior cranio-facial bony structures. Therefore, for the measurement of spheno-frontal distance we selected the most anterior border of the bone, which can be seen in most cases.
Second, we used the lower edge of the frontal bone rather than the nasion because the frontal bone is more readily identified on fetal ultrasound and this was reflected by a good reproducibility of the measurements, which were within 1.2 mm in 95% of the cases assessed by two independent operators.
Previous sonographic studies have demonstrated that second and third trimester fetuses with trisomy 21 show signs of mid-facial hypoplasia and that these can be assessed by measuring nasal bone (NB) length 1 , prenasal thickness 2 (PT) and prefrontal space ratio 5 (PFSR). Our results suggest that a contribution to the flat face of fetuses with trisomy 21 is also provided by a shorter spheno-frontal distance, which could be due to dorsal displacement of the lower portion of the frontal bone ( Figure 1) .
A recent retrospective study compared the measurements of several ultrasound markers between a large number of fetuses with trisomy 21 and normal cases,
showing that the most significant differences were observed for PT-NB ratio and PFSR 12 . At a false positive rate of 5%, PT-NB ratio and PFSR were abnormal in about 86% and 80% of trisomy 21 fetuses, respectively. Our results are not suitable to determine the performance of sonographic measurement of spheno-frontal distance in second trimester screening for trisomy 21, because the measurements were undertaken on stored 3D volumes from two selected groups of patients.
Therefore, larger studies would be required to define the clinical value of measuring the spheno-frontal distance in routine practice and to assess the feasibility and reproducibility of the measurements using two-dimensional ultrasound.
In the last 15 years, screening for trisomy 21 has seen a major shift in timing of screening towards the first trimester of pregnancy, due to the widespread introduction of combined testing at 11-13 weeks' gestation, which can detect about 90% of cases with trisomy 21 for a false positive rate of about 5% 13 . More recently, it has been shown that cell-free DNA (cfDNA) testing in the maternal blood from 10 weeks' gestation can detect more than 99% of fetuses with trisomy 21, for a false positive rate of about 0.1% 14 . Therefore, the prevalence of trisomy 21 in the second trimester of pregnancy in women who had prior screening by combined and/or cfDNA testing is very low and the routine use of sonographic soft-markers in these cases may produce a significant increase in the invasive testing rate, especially if the 95th or the 5th percentile of a given measurement is taken as the cut-off. However, second trimester pregnancies that have not undergone prior testing can benefit from assessment of sonographic markers to calculate a patient-specific risk for trisomy 21, which can be obtained multiplying the background maternal age-related risk by the positive or negative likelihood ratio for each of the examined markers 
